Epstein-barr virus in multiple sclerosis

[1]  H. Lassmann,et al.  Epstein–Barr virus in the multiple sclerosis brain: a controversial issue—report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria , 2011, Brain : a journal of neurology.

[2]  K. Dear,et al.  Current and past Epstein-Barr virus infection in risk of initial CNS demyelination , 2011, Neurology.

[3]  E. Mowry,et al.  Common viruses associated with lower pediatric multiple sclerosis risk , 2011, Neurology.

[4]  E. Wherry.  T cell exhaustion , 2011, Nature Immunology.

[5]  J. Mcleod,et al.  Migration and multiple sclerosis in immigrants to Australia from United Kingdom and Ireland: a reassessment. I. Risk of MS by age at immigration , 2011, Journal of Neurology.

[6]  R. Reynolds,et al.  Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look. , 2010, Brain : a journal of neurology.

[7]  A. Odén,et al.  High risk of MS in Iranian immigrants in Gothenburg, Sweden , 2010, Multiple sclerosis.

[8]  A. Ascherio,et al.  Primary infection with the Epstein‐Barr virus and risk of multiple sclerosis , 2010, Annals of neurology.

[9]  P. Sørensen,et al.  The changing demographic pattern of multiple sclerosis epidemiology , 2010, The Lancet Neurology.

[10]  C. Stadelmann,et al.  Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis , 2010, Neurology.

[11]  K. Münger,et al.  99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: Epstein–Barr virus and multiple sclerosis: epidemiological evidence , 2010, Clinical and experimental immunology.

[12]  X. Montalban,et al.  Antiviral immune response in patients with multiple sclerosis and healthy siblings , 2010, Multiple sclerosis.

[13]  A. Swerdlow,et al.  Infectious mononucleosis in university students in the United kingdom: evaluation of the clinical features and consequences of the disease. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  E. Kahana,et al.  Multiple sclerosis: geoepidemiology, genetics and the environment. , 2010, Autoimmunity reviews.

[15]  J. Lünemann,et al.  Elevated Epstein–Barr virus‐encoded nuclear antigen‐1 immune responses predict conversion to multiple sclerosis , 2010, Annals of neurology.

[16]  M. Sofroniew,et al.  Astrocytes: biology and pathology , 2009, Acta Neuropathologica.

[17]  D. Hafler,et al.  Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. , 2009, Brain : a journal of neurology.

[18]  M. Wallin,et al.  Multiple sclerosis in the Faroe Islands. 8. Notifiable diseases , 2009, Acta neurologica Scandinavica.

[19]  G. Giovannoni,et al.  Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. , 2009, Brain : a journal of neurology.

[20]  K. Schmierer,et al.  Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI , 2009, Neurology.

[21]  S. Chow,et al.  Intestinal parasitic infections amongst Orang Asli (indigenous) in Malaysia: has socioeconomic development alleviated the problem? , 2009, Tropical biomedicine.

[22]  M. Pender.  Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. , 2009, Autoimmunity reviews.

[23]  R. Voltz,et al.  The intrathecal, polyspecific antiviral immune response: Specific for MS or a general marker of CNS autoimmunity? , 2009, Journal of the Neurological Sciences.

[24]  J. Grange,et al.  Is the risk of multiple sclerosis related to the ‘biography’ of the immune system? , 2009, Journal of Neurology.

[25]  J. Lindsey,et al.  Quantitative PCR for Epstein–Barr virus DNA and RNA in multiple sclerosis , 2009, Multiple sclerosis.

[26]  M. Ramanathan,et al.  Epstein–Barr virus is associated with grey matter atrophy in multiple sclerosis , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[27]  R. Steffensen,et al.  Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis , 2009, Multiple sclerosis.

[28]  S. Burrows,et al.  Decreased T cell reactivity to Epstein–Barr virus infected lymphoblastoid cell lines in multiple sclerosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[29]  J. Roudier,et al.  Epstein-Barr virus in autoimmune diseases. , 2008, Best practice & research. Clinical rheumatology.

[30]  J. Lünemann,et al.  BROADENED AND ELEVATED HUMORAL IMMUNE RESPONSE TO EBNA1 IN PEDIATRIC MULTIPLE SCLEROSIS , 2008, Neurology.

[31]  M. Salvetti,et al.  B cells and multiple sclerosis , 2008, The Lancet Neurology.

[32]  A. Ascherio,et al.  Human endogenous retrovirus-K18 Env as a risk factor in multiple sclerosis , 2008, Multiple sclerosis.

[33]  J. Lünemann,et al.  EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-γ and IL-2 , 2008, The Journal of experimental medicine.

[34]  L. Nyström,et al.  EBNA-1 reactivity and HLA DRB1*1501 as statistically independent risk factors for multiple sclerosis: a case-control study , 2008, Multiple sclerosis.

[35]  A. Lutterotti,et al.  Cerebrospinal Fluid B Cells Correlate with Early Brain Inflammation in Multiple Sclerosis , 2008, PloS one.

[36]  G. Pantaleo,et al.  Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. , 2008, Brain : a journal of neurology.

[37]  C. Sample,et al.  Epstein-Barr virus vaccine development: a lytic and latent protein cocktail. , 2008, Frontiers in bioscience : a journal and virtual library.

[38]  J. Rioux,et al.  Integrating risk factors , 2008, Neurology.

[39]  J. Potter,et al.  Association of Epstein-Barr virus antibody titers with a human IL-10 promoter polymorphism in Japanese women , 2008, Journal of autoimmune diseases.

[40]  A. Ascherio.  Epstein–Barr virus in the development of multiple sclerosis , 2008, Expert review of neurotherapeutics.

[41]  D. Arnold,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.

[42]  M. Moutschen,et al.  Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. , 2007, The Journal of infectious diseases.

[43]  R. Reynolds,et al.  Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain , 2007, The Journal of experimental medicine.

[44]  H. Kettenmann,et al.  Microglia: active sensor and versatile effector cells in the normal and pathologic brain , 2007, Nature Neuroscience.

[45]  A. Bar-Or,et al.  Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study , 2007, The Lancet Neurology.

[46]  S. Gabriel,et al.  Risk alleles for multiple sclerosis identified by a genomewide study. , 2007, The New England journal of medicine.

[47]  D. Hafler,et al.  Protective and therapeutic role for αB-crystallin in autoimmune demyelination , 2007, Nature.

[48]  A. Ascherio,et al.  Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors , 2007, Annals of neurology.

[49]  J. Libbey,et al.  Molecular Mimicry in Multiple Sclerosis , 2007, International Review of Neurobiology.

[50]  J. Lünemann,et al.  Epstein-Barr virus and multiple sclerosis , 2007, Current neurology and neuroscience reports.

[51]  H. Lassmann.  New concepts on progressive multiple sclerosis , 2007, Current neurology and neuroscience reports.

[52]  P. Kennedy,et al.  An attempt to investigate the presence of Epstein Barr virus in multiple sclerosis and normal control brain tissue , 2007, Journal of Neurology.

[53]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[54]  A. Ascherio,et al.  Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. , 2006, JAMA.

[55]  F. Hanefeld,et al.  High seroprevalence of Epstein–Barr virus in children with multiple sclerosis , 2006, Neurology.

[56]  Philip J. R. Goulder,et al.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.

[57]  J. Lünemann,et al.  Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. , 2006, Brain : a journal of neurology.

[58]  A. Ascherio,et al.  Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. , 2006, Archives of neurology.

[59]  F. Aloisi,et al.  Lymphoid neogenesis in chronic inflammatory diseases , 2006, Nature Reviews Immunology.

[60]  A. Ascherio,et al.  Infectious mononucleosis and risk for multiple sclerosis: A meta‐analysis , 2006, Annals of neurology.

[61]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[62]  D. Crawford,et al.  Epstein-Barr virus: the impact of scientific advances on clinical practice. , 2006, Blood.

[63]  J. Jakobsen,et al.  Presence of Epstein–Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: associations with disease activity , 2005, Acta neurologica Scandinavica.

[64]  K. Kyvik,et al.  Risk for multiple sclerosis in dizygotic and monozygotic twins , 2005, Multiple sclerosis.

[65]  W. Hop,et al.  Epstein-Barr virus and disease activity in multiple sclerosis , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[66]  L. Adorini,et al.  Manipulating dendritic cells to induce regulatory T cells. , 2005, Microbes and infection.

[67]  J. Friedman,et al.  A randomized clinical trial of valacyclovir in multiple sclerosis , 2005, Multiple sclerosis.

[68]  D. Spiegelman,et al.  Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. , 2005, JAMA.

[69]  K. Büssow,et al.  Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. , 2005, The Journal of clinical investigation.

[70]  D. Thorley-Lawson,et al.  Terminal Differentiation into Plasma Cells Initiates the Replicative Cycle of Epstein-Barr Virus In Vivo , 2005, Journal of Virology.

[71]  A. Ascherio,et al.  Plasma viral load of Epstein–Barr virus and risk of multiple sclerosis , 2004, European journal of neurology.

[72]  L. Young,et al.  Epstein–Barr virus: 40 years on , 2004, Nature Reviews Cancer.

[73]  A. Sadovnick,et al.  Vitamin D intake and incidence of multiple sclerosis [1] (multiple letters) , 2004 .

[74]  A. Uccelli,et al.  Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[75]  J. Dillner,et al.  An altered immune response to Epstein-Barr virus in multiple sclerosis , 2004, Neurology.

[76]  R. Tellier,et al.  Epstein-Barr virus in pediatric multiple sclerosis. , 2004, JAMA.

[77]  B. Serafini,et al.  Detection of Ectopic B‐cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis , 2004, Brain pathology.

[78]  P. Höllsberg,et al.  A role of late Epstein–Barr virus infection in multiple sclerosis , 2004, Acta neurologica Scandinavica.

[79]  D. Thorley-Lawson,et al.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas. , 2004, The New England journal of medicine.

[80]  D. Bourdette,et al.  CD4 T‐cell epitopes of human α B‐crystallin , 2004 .

[81]  W. Willett,et al.  Vitamin D intake and incidence of multiple sclerosis , 2004, Neurology.

[82]  J. Haines,et al.  The genetic epidemiology of multiple sclerosis , 2003, Journal of Neuroimmunology.

[83]  D. Spiegelman,et al.  Multiple sclerosis and Epstein-Barr virus. , 2003, JAMA.

[84]  Arne Svejgaard,et al.  A functional and structural basis for TCR cross-reactivity in multiple sclerosis , 2002, Nature Immunology.

[85]  S. Ekholm,et al.  A randomized, double-blind, placebo-controlled MRI study of anti–herpes virus therapy in MS , 2002, Neurology.

[86]  D Spiegelman,et al.  Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. , 2001, JAMA.

[87]  G. Niedobitek,et al.  Epstein-Barr virus infection and human malignancies. , 2001, International journal of experimental pathology.

[88]  G. Rosati,et al.  The prevalence of multiple sclerosis in the world: an update , 2001, Neurological Sciences.

[89]  J. Cohen,et al.  Epstein-Barr virus infection. , 2000, The New England journal of medicine.

[90]  P. Trillenberg,et al.  Association between clinical disease activity and Epstein–Barr virus reactivation in MS , 2000, Neurology.

[91]  J. Bajramovic,et al.  Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis , 2000, Journal of Neuroimmunology.

[92]  J. Newcombe,et al.  Presentation of αB-Crystallin to T Cells in Active Multiple Sclerosis Lesions: An Early Event Following Inflammatory Demyelination1 , 2000, The Journal of Immunology.

[93]  M. V. van Stipdonk,et al.  EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. , 1999, Journal of immunology.

[94]  D. Thorley-Lawson,et al.  EBV persistence in memory B cells in vivo. , 1998, Immunity.

[95]  Jaap M Middeldorp,et al.  Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas. , 1997, Journal of clinical pathology.

[96]  D. Thorley-Lawson,et al.  Is EBV persistence in vivo a model for B cell homeostasis? , 1996, Immunity.

[97]  D. Thorley-Lawson,et al.  Epstein-Barr virus and the B cell: that's all it takes. , 1996, Trends in microbiology.

[98]  P. Gasque,et al.  Identification and characterization of complement C3 receptors on human astrocytes. , 1996, Journal of immunology.

[99]  L. Young,et al.  Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state , 1994, Journal of virology.

[100]  M. Munch,et al.  Increased risk of multiple sclerosis after late Epstein-Barr virus infection. A historical prospective study , 1994, Journal of Neuroimmunology.

[101]  S. Love,et al.  Absence of Epstein-Barr virus RNA in multiple sclerosis as assessed by in situ hybridisation. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[102]  B. Heap.  Notifiable diseases. , 1992, BMJ.

[103]  J. Adams,et al.  1,25-Dihydroxyvitamin-D3 regulation of interleukin-2 and interleukin-2 receptor levels and gene expression in human T cells. , 1989, Molecular immunology.

[104]  R. Detels,et al.  A case‐control study of multiple sclerosis , 1989, Neurology.

[105]  J. Merrett,et al.  T-cell-mediated suppression of Epstein-Barr virus-induced B lymphocyte activation in multiple sclerosis. , 1988, Clinical immunology and immunopathology.

[106]  H. B. Warner,et al.  Multiple sclerosis etiology--an Epstein-Barr virus hypothesis. , 1988, Medical hypotheses.

[107]  A. Hossain.  Seroepidemiology of Epstein-Barr virus infections in a developing country. , 1987, Journal of tropical pediatrics.

[108]  D. Katz,et al.  Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. , 1987, Immunology.

[109]  J. Kurtzke,et al.  Multiple sclerosis in the Faroe Islands. , 1986, Neurology.

[110]  G. Ellison,et al.  Increased prevalence and titer of Epstein‐Barr virus antibodies in patients with multiple sclerosis , 1985, Annals of neurology.

[111]  S. Manolagas,et al.  1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. , 1984, Science.

[112]  S. Manolagas,et al.  1,25-dihydroxyvitamin D3 receptors in human leukocytes. , 1983, Science.

[113]  G. Ellison,et al.  Epstein-Barr virus antibodies in multiple sclerosis. , 1980, Archives of neurology.

[114]  M. Haire,et al.  INCREASED TENDENCY TO SPONTANEOUS IN-VITRO LYMPHOCYTE TRANSFORMATION IN CLINICALLY ACTIVE MULTIPLE SCLEROSIS , 1979, The Lancet.

[115]  S. Agarwal,et al.  Letter: Alpha-fetoprotein in Indian childhood cirrhosis. , 1974, Lancet.

[116]  A. Evans,et al.  Prospective studies of a group of Yale University freshmen. I. Occurrence of infectious mononucleosis. , 1971, The Journal of infectious diseases.

[117]  T. Holmøy,et al.  Cerebrospinal fluid CD4+ T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein , 2011, Journal of NeuroVirology.

[118]  T. Holmøy.  Vitamin D status modulates the immune response to Epstein Barr virus: Synergistic effect of risk factors in multiple sclerosis. , 2008, Medical hypotheses.

[119]  P. Sørensen,et al.  Multiple sclerosis after infectious mononucleosis. , 2007, Archives of neurology.

[120]  G. Ellison,et al.  Epstein-Barr virus antibodies and histocompatibility type in multiple sclerosis. , 1977, Transactions of the American Neurological Association.